ASX & MEDIA RELEASE
29 SEPTEMBER, 2011

NOVOGEN ANNOUNCES US$2 MILLION INVESTMENT IN MARSHALL EDWARDS

Sydney Australia – 29 September, 2012 – Novogen Limited (ASX: NRT; NASDAQ: NVGN) today announced the that it has entered into a definitive agreement with its majority owned subsidiary, Marshall Edwards, Inc., to purchase common stock in a private placement for a total investment of US$2 million through the purchase of approximately 1.33 million shares of Marshall Edwards, Inc. common stock.

In making the announcement, William D Rueckert, Chairman said "Marshall Edwards represents our Company's most important asset and we are pleased to be able to continue to support its exciting drug development programs. We look forward to providing possible additional support in the future and the success of the programs."

Dr Dan Gold, Marshall Edwards President and Chief Executive Officer said the following: "This transaction is another indication of Novogen's ongoing support of Marshall Edwards and our emerging oncology programs.

"Net proceeds from this offering will be used to continue development of our two lead drug candidates, ME-143 and ME-344, and will enable us to advance these programs to meaningful clinical data points next year that we believe can create significant value for our shareholders."

The offering is expected to close on 30 September, 2011, subject to certain customary closing conditions.

About Novogen Limited

Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

About Marshall Edwards

Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The company's lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

ISSUED FOR	**:**	**NOVOGEN LIMITED**
LISTINGS	**:**	**ASX (CODE NRT), NASDAQ (CODE NVGN).**
FOR FURTHER INFORMATION	**:**	**MR BILL RUECKERT, CHAIRMAN, NOVOGEN LIMITED** **TEL (02) 9878 0088** **http://www.novogen.com**
ISSUED BY	**:**	**WESTBROOK COMMUNICATIONS**
CONTACT	**:**	**IAN WESTBROOK TEL (02) 9231 0922**